Osteopontin (OPN) is an arginine-glycine-aspartate (RGD)-containing acidic phosphoprotein implicated in bone morphogenesis, kidney function, tumor metastasis, and bacterial resistance. While expression of OPN in normal tissues appears restricted to mineralizing and several non- mineralizing tissues, we have found that OPN MRNA and protein increase dramatically in several different tissue injury scenarios including renal tubulointerstitial fibrosis, arterial intimal hyperplasia, atherosclerosis, and myocardial necrosis, implying a broad role for OPN during tissue injury and wound repair. These roles may include facilitating cell-cell or cell-substrate interactions. In specific animal models of disease, we have demonstrated by in situ hybridization and immunocytochemical techniques that OPN is specifically upregulated in tubular epithelium., smooth muscle cells and macrophages depending on the site and type of injury. This data suggests that lineage and injury- related factors probably work in a concerted fashion to regulate OPN expression in vivo. While regulation of OPN expression in bone and epidermal cells by systemically active hormones has been addressed, little is known about control of OPN expression by locally-derived factors present in wounded tissue. This project seeks to understand OPN functions and expression during tissue injury, focussing on renal and vascular models, in two ways: 1) by looking at the effect of OPN on macrophage function in vitro and in vivo and 20 by delineating the basal control of OPN gene expression in renal tubular epithelial cells, macrophage, and smooth muscle cells, and its modification by locally-derived factors thought to be present in wounded tissue. These studies may help to identify possible pharmacological approaches to control OPN synthesis under situations where its presence or absence may be deleterious. An understanding of the cis-acting elements involved in local control of OPN expression might also identify an 'injury-specific' promoter which could be useful for regulating expression of therapeutic transgenes in the future.
Liu, Gang; Changsirikulchai, Siribha; Hudkins, Kelly L et al. (2008) Identification of platelet-derived growth factor D in human chronic allograft nephropathy. Hum Pathol 39:393-402 |
Petermann, Arndt T; Pippin, Jeffrey; Durvasula, Raghu et al. (2005) Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int 67:157-66 |
Vaughan, Michael R; Pippin, Jeffrey W; Griffin, Sian V et al. (2005) ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo. Kidney Int 68:133-44 |
Griffin, Sian V; Krofft, Ronald D; Pippin, Jeffrey W et al. (2005) Limitation of podocyte proliferation improves renal function in experimental crescentic glomerulonephritis. Kidney Int 67:977-86 |
Griffin, Sian V; Hiromura, Keiju; Pippin, Jeffrey et al. (2004) Cyclin-dependent kinase 5 is a regulator of podocyte differentiation, proliferation, and morphology. Am J Pathol 165:1175-85 |
Cybulsky, Andrey V; Takano, Tomoko; Papillon, Joan et al. (2004) Renal expression and activity of the germinal center kinase SK2. Am J Physiol Renal Physiol 286:F16-25 |
Durvasula, Raghu V; Petermann, Arndt T; Hiromura, Keiju et al. (2004) Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 65:30-9 |
Hudkins, Kelly L; Gilbertson, Debra G; Carling, Matthew et al. (2004) Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J Am Soc Nephrol 15:286-98 |
Francki, Aleksandar; McClure, Timothy D; Brekken, Rolf A et al. (2004) SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 91:915-25 |
Petermann, Arndt; Hiromura, Keiju; Pippin, Jeffrey et al. (2004) Differential expression of d-type cyclins in podocytes in vitro and in vivo. Am J Pathol 164:1417-24 |
Showing the most recent 10 out of 150 publications